Stocks Health care BCTX
NASDAQ · Health careBriaCell Therapeutics Corp. (BCTX)
It posted a net loss of $30.7M. At April 30, 2026 it held $6.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on June 9, 2026.
Key facts about BriaCell Therapeutics Corp.
- Net worth
- BriaCell Therapeutics Corp. has a market value (market cap) of $32.5M at the latest share price, and shareholders' equity of $23.4M on its balance sheet at April 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $28.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on June 9, 2026 and covers the period to April 30, 2026. Open on SEC EDGAR
- Next earnings report
- BriaCell Therapeutics Corp.'s next report was expected around October 15, 2026 and is not on file with the SEC yet.
What BriaCell Therapeutics Corp. does
BriaCell Therapeutics Corp. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BCTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$26.3M | -$62.19 | n/a |
| 2024 | n/a | -$4.8M | -$43.68 | -$24.6M |
| 2023 | n/a | -$20.3M | -$195.81 | n/a |
| 2022 | n/a | -$26.8M | -$260.57 | n/a |
| 2021 | n/a | -$13.8M | -$460.90 | n/a |
| 2021 | n/a | -$4M | n/a | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What BriaCell Therapeutics Corp. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- June 26, 2026
- June 9, 2026
- June 3, 2026
- March 31, 2026
- March 10, 2026
- March 9, 2026
- February 26, 2026Delisting notice 25-NSE
- February 20, 2026Other event 8-K
- February 12, 2026Proxy statement DEF 14A
- January 23, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running BriaCell Therapeutics Corp. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns BCTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Plambeck Jeremy Myung Jae13G, passive | 100% | October 10, 2025 |
| Marc Lustig13D, may seek influence with 1 related filers | 10.7% | December 12, 2024 |
| Kenneth Griffin13G, passive with 6 related filers | 9.99% | January 23, 2026 |
| Richard Abbe13G, passive with 2 related filers | 9.1% | July 28, 2025 |
Largest institutional holders
Insiders
Questions about BCTX
What does BriaCell Therapeutics Corp. do?
BriaCell Therapeutics Corp. is a company in the Health care sector, listed on NASDAQ as BCTX. Its shares trade on NASDAQ under the ticker BCTX.
What is BriaCell Therapeutics Corp.'s net worth?
BriaCell Therapeutics Corp. has a market value (market cap) of $32.5M at the latest share price, and shareholders' equity of $23.4M on its balance sheet at April 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is BriaCell Therapeutics Corp. profitable?
No. Over the twelve months to April 30, 2026 it reported a net loss of $30.7M.
When did BriaCell Therapeutics Corp. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on June 9, 2026. It covers the period to April 30, 2026. Its newest filing of any kind is the investor disclosure from June 26, 2026.
When is BriaCell Therapeutics Corp.'s next earnings report?
BriaCell Therapeutics Corp.'s next report was expected around October 15, 2026 and is not on file with the SEC yet.
Similar companies
Compare BCTX with
Follow BCTX
Get an email when BriaCell Therapeutics Corp. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values BriaCell Therapeutics Corp. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.